Rochester,NY 8/12/2009 11:19:23 PM
Amgen, Inc. AMGN-Amgen's bone-density treatment obtains NEJM nod and FDA scrutiny
Amgen, Inc
Denosumab, an antibody being studied for the treatment of osteoporosis and other bone related issues is reportedly indicating positive findings, according to a study published and released Tuesday in the New England Journal of Medicine.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
The results propelled denosumab developer Amgen’s stock upward on Wall Street. At close Tuesday, Amgen stock was up 2.56 percent to $62.81.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
